Nature Communications (Nov 2022)
Structural characterization of protective non-neutralizing antibodies targeting Crimean-Congo hemorrhagic fever virus
- Ian A. Durie,
- Zahra R. Tehrani,
- Elif Karaaslan,
- Teresa E. Sorvillo,
- Jack McGuire,
- Joseph W. Golden,
- Stephen R. Welch,
- Markus H. Kainulainen,
- Jessica R. Harmon,
- Jarrod J. Mousa,
- David Gonzalez,
- Suzanne Enos,
- Iftihar Koksal,
- Gurdal Yilmaz,
- Hanife Nur Karakoc,
- Sanaz Hamidi,
- Cansu Albay,
- Jessica R. Spengler,
- Christina F. Spiropoulou,
- Aura R. Garrison,
- Mohammad M. Sajadi,
- Éric Bergeron,
- Scott D. Pegan
Affiliations
- Ian A. Durie
- Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia
- Zahra R. Tehrani
- Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine
- Elif Karaaslan
- Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention
- Teresa E. Sorvillo
- Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention
- Jack McGuire
- Division of Biomedical Sciences, University of California Riverside
- Joseph W. Golden
- Virology Division, United States Army Medical Research Institute of Infectious Diseases
- Stephen R. Welch
- Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention
- Markus H. Kainulainen
- Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention
- Jessica R. Harmon
- Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention
- Jarrod J. Mousa
- Department of Infectious Diseases, University of Georgia College of Veterinary Medicine
- David Gonzalez
- Division of Biomedical Sciences, University of California Riverside
- Suzanne Enos
- Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia
- Iftihar Koksal
- Department of Infectious Disease and Clinical Microbiology, Acibadem University Atakent Hospital
- Gurdal Yilmaz
- Department of Infectious Diseases, Karadeniz Technical University School of Medicine
- Hanife Nur Karakoc
- Department of Infectious Disease and Clinical Microbiology, Bitlis State Hospital
- Sanaz Hamidi
- Department of Infectious Diseases, Karadeniz Technical University School of Medicine
- Cansu Albay
- Department of Infectious Diseases, Karadeniz Technical University School of Medicine
- Jessica R. Spengler
- Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention
- Christina F. Spiropoulou
- Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention
- Aura R. Garrison
- Virology Division, United States Army Medical Research Institute of Infectious Diseases
- Mohammad M. Sajadi
- Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine
- Éric Bergeron
- Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia
- Scott D. Pegan
- Division of Biomedical Sciences, University of California Riverside
- DOI
- https://doi.org/10.1038/s41467-022-34923-0
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 12
Abstract
There are currently no approved treatments for Crimean-Congo Hemorrhagic Fever Virus (CCHFV) infection. In this study, the authors structurally characterize the epitope targeted by protective non-neutralizing mouse and human antibodies and provide insights into their broad range potential against various CCHFV strains.
